AbbVie Inc. $ABBV Position Boosted by Synergy Asset Management LLC

Synergy Asset Management LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 703.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 180,179 shares of the company’s stock after acquiring an additional 157,767 shares during the quarter. AbbVie makes up 4.3% of Synergy Asset Management LLC’s portfolio, making the stock its 3rd biggest position. Synergy Asset Management LLC’s holdings in AbbVie were worth $45,340,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. RWQ Financial Management Services Inc. boosted its holdings in AbbVie by 135.9% in the second quarter. RWQ Financial Management Services Inc. now owns 54,700 shares of the company’s stock valued at $13,765,000 after acquiring an additional 31,510 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in AbbVie by 5.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 495,003 shares of the company’s stock valued at $124,563,000 after purchasing an additional 27,237 shares during the period. Hidden Cove Wealth Management LLC raised its holdings in AbbVie by 16.5% in the 2nd quarter. Hidden Cove Wealth Management LLC now owns 2,600 shares of the company’s stock worth $654,000 after purchasing an additional 369 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. raised its holdings in AbbVie by 368.4% in the 2nd quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,288 shares of the company’s stock worth $324,000 after purchasing an additional 1,013 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of AbbVie by 1.1% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 324,551 shares of the company’s stock worth $81,670,000 after purchasing an additional 3,394 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of research reports. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Piper Sandler reaffirmed an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Bank of America increased their target price on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $275.50.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Stock Performance

Shares of ABBV opened at $249.20 on Friday. The stock has a market cap of $440.29 billion, a PE ratio of 70.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm’s 50-day simple moving average is $244.94 and its two-hundred day simple moving average is $226.12.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period last year, the business earned $2.97 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.